Karyopharm director granted 15,508 RSUs

Karyopharm Therapeutics Inc. director Chen Schor reported an award of 15,508 shares of common stock in the form of restricted stock units (RSUs) granted at no cash cost as director compensation.

Rhea-AI Filing Summary

Karyopharm Therapeutics Inc. director Chen Schor reported an award of 15,508 shares of common stock in the form of restricted stock units (RSUs) granted at no cash cost as director compensation.

The RSUs were granted under the 2022 Equity Incentive Plan and convert into common stock on a one-for-one basis. They vest 100% on May 21, 2027, with delivery of the underlying shares deferred until the earlier of Schor’s separation from service or a change-in-control event. The filing shows no open-market buying or selling, only a stock-based compensation grant resulting in direct ownership of 15,508 shares after the award.

Insider Trade Summary

Grant/Award: 15,508 shares

Grant/Award 1 txn

Insider Schor Chen

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	15,508	$0.00	$0.00

Holdings After Transaction: Common Stock — 15,508 shares (Direct)

Footnotes (1)

1. F1. Represents the award of restricted stock units ("RSUs") pursuant to the Karyopharm Therapeutics Inc. 2022 Equity Incentive Plan, as amended. RSUs convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. The RSUs vest 100% on May 21, 2027; however, delivery of the shares is deferred until the earlier of (a) the date of the director's separation from service to Karyopharm Therapeutics Inc. and (b) a change-in-control event.

Key Figures

RSU grant size: 15,508 shares Grant price per share: $0.0000 per share Shares owned after grant: 15,508 shares +1 more

4 metrics

RSU grant size 15,508 shares Restricted stock units granted to director on May 21, 2026

Grant price per share $0.0000 per share Reported transaction price for RSU award

Shares owned after grant 15,508 shares Total common stock directly owned following the RSU award

Vesting date May 21, 2027 RSUs vest 100% on this date

Key Terms

restricted stock units ("RSUs"), 2022 Equity Incentive Plan, change-in-control event

3 terms

restricted stock units ("RSUs") financial

"Represents the award of restricted stock units ("RSUs") pursuant to the Karyopharm Therapeutics Inc. 2022 Equity Incentive Plan, as amended."

Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.

2022 Equity Incentive Plan financial

"Represents the award of restricted stock units ("RSUs") pursuant to the Karyopharm Therapeutics Inc. 2022 Equity Incentive Plan, as amended."

change-in-control event financial

"delivery of the shares is deferred until the earlier of (a) the date of the director's separation from service to Karyopharm Therapeutics Inc. and (b) a change-in-control event."

FAQ

What did Karyopharm (KPTI) director Chen Schor report on this Form 4?

Chen Schor reported receiving 15,508 restricted stock units (RSUs) of Karyopharm common stock as a grant. The award is stock-based compensation, carries no cash purchase price, and increases his directly owned shares to 15,508 following the transaction.

How many Karyopharm (KPTI) shares were granted to Chen Schor?

Chen Schor was granted 15,508 restricted stock units (RSUs), each representing one share of Karyopharm common stock. All 15,508 shares are reported as directly owned after the transaction, reflecting a single compensation-related equity award rather than open-market trading.

At what price were Chen Schor’s Karyopharm (KPTI) RSUs granted?

The 15,508 restricted stock units (RSUs) granted to Chen Schor show a transaction price of $0.0000 per share. This indicates a compensation grant with no cash paid by the director, typical for stock awards made under an equity incentive plan.

When do Chen Schor’s Karyopharm (KPTI) RSUs vest and settle?

The RSUs vest 100% on May 21, 2027, subject to continued service. Delivery of the underlying Karyopharm shares is deferred until the earlier of Chen Schor’s separation from service or a change-in-control event, according to the award’s footnote disclosure.

What plan governs Chen Schor’s new Karyopharm (KPTI) RSU grant?

The RSU grant to Chen Schor was made under the Karyopharm Therapeutics Inc. 2022 Equity Incentive Plan, as amended. This plan authorizes stock-based compensation awards, with these RSUs converting into common stock on a one-for-one basis upon settlement.

Is Chen Schor’s Karyopharm (KPTI) Form 4 a buy or a sale of shares?

The Form 4 reports an acquisition of 15,508 shares through a restricted stock unit (RSU) grant, not a market buy or sale. It is classified as a grant, award, or other acquisition, with no open-market purchase or disposition of existing Karyopharm shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/26/2026 - 04:14 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Schor Chen

(Last) (First) (Middle)

C/O KARYOPHARM THERAPEUTICS INC.

85 WELLS AVENUE

(Street)

NEWTON MASSACHUSETTS 02459

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Karyopharm Therapeutics Inc. [ KPTI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/21/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/21/2026		A		15,508(1)	A	$0	15,508	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents the award of restricted stock units ("RSUs") pursuant to the Karyopharm Therapeutics Inc. 2022 Equity Incentive Plan, as amended. RSUs convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. The RSUs vest 100% on May 21, 2027; however, delivery of the shares is deferred until the earlier of (a) the date of the director's separation from service to Karyopharm Therapeutics Inc. and (b) a change-in-control event.

	/s/ Nancy Smith, Attorney-in-Fact for Chen Schor	05/26/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)